Which medication is particularly considered in HFrEF patients with concomitant atrial fibrillation to reduce hospitalizations?

Which medication is particularly considered in HFrEF patients with concomitant atrial fibrillation to reduce hospitalizations?

• A. Digoxin
• B. Carvedilol
• C. Spironolactone
• D. Furosemide

Answer: (A)

In this scenario, the goal is to improve heart failure symptoms while also controlling the rapid heart rate that comes with atrial fibrillation. Digoxin stands out because it does both: it increases the heart’s contractility (positive inotropy) to help with systolic function, and it slows conduction through the AV node via vagal effects to control the ventricular rate in atrial fibrillation. By improving filling time and reducing tachycardia, patients tend to have fewer decompensations and thus fewer hospitalizations. Other drugs have important roles in HFrEF, but their primary benefits aren’t specifically about reducing hospitalizations in the setting of atrial fibrillation with HF. Beta-blockers like carvedilol reduce mortality and hospitalization in HFrEF broadly but aren’t targeted to rate control in AF. Spironolactone lowers HF-related hospitalizations overall via aldosterone antagonism, and furosemide relieves congestion, but neither is chosen specifically for AF-related hospitalization reduction. Digoxin’s dual action makes it especially useful when AF coexists with HFrEF to cut HF-related hospitalizations, with careful monitoring for toxicity and kidney function.

In this scenario, the goal is to improve heart failure symptoms while also controlling the rapid heart rate that comes with atrial fibrillation. Digoxin stands out because it does both: it increases the heart’s contractility (positive inotropy) to help with systolic function, and it slows conduction through the AV node via vagal effects to control the ventricular rate in atrial fibrillation. By improving filling time and reducing tachycardia, patients tend to have fewer decompensations and thus fewer hospitalizations.

Other drugs have important roles in HFrEF, but their primary benefits aren’t specifically about reducing hospitalizations in the setting of atrial fibrillation with HF. Beta-blockers like carvedilol reduce mortality and hospitalization in HFrEF broadly but aren’t targeted to rate control in AF. Spironolactone lowers HF-related hospitalizations overall via aldosterone antagonism, and furosemide relieves congestion, but neither is chosen specifically for AF-related hospitalization reduction. Digoxin’s dual action makes it especially useful when AF coexists with HFrEF to cut HF-related hospitalizations, with careful monitoring for toxicity and kidney function.